Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Seer, Inc. SEER

Healthcare  —  Biotechnology
1.91 0.11 6.11% as of 25 Sep
Market cap
$103.6M
P/E
0.0×
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Seer, Inc. (SEER) Business Profile

Updated before January 2025

Company Overview

Seer, Inc. (SEER) is a biotechnology company that specializes in the development and commercialization of innovative solutions for proteomics, the large-scale study of proteins. Founded in 2017 and headquartered in Redwood City, California, Seer was established with the mission of transforming the field of proteomics by enabling unprecedented access to the proteome. The company was co-founded by Omid Farokhzad, a renowned scientist and entrepreneur in the biotechnology space. Seer’s leadership team includes experienced professionals from the biotechnology and life sciences industries, with Omid Farokhzad serving as the Chairman and CEO. The company went public in December 2020, trading on the NASDAQ under the ticker symbol SEER.

Core Business Segments

Seer operates primarily in the field of proteomics, offering cutting-edge technologies and solutions that enable researchers to analyze proteins at an unprecedented scale and depth. The company’s core business segments include:

Proteograph Product Suite

The Proteograph Product Suite is Seer’s flagship offering. It is a proprietary platform designed to provide researchers with a comprehensive view of the proteome. The suite includes:

  • Proteograph Assay Kits: These kits enable the capture and analysis of proteins from complex biological samples.
  • Proteograph Instrumentation: Advanced hardware that automates the proteomics workflow, ensuring high precision and reproducibility.
  • Proteograph Software: A suite of analytical tools that allow researchers to interpret proteomics data effectively.

Services and Collaborations

Seer also offers services to support its customers in their proteomics research. These include:

  • Custom Proteomics Services: Tailored solutions for specific research needs.
  • Collaborative Research Programs: Partnerships with academic institutions, pharmaceutical companies, and other organizations to advance proteomics research.

Data Analytics and Insights

Seer provides advanced data analytics solutions to help researchers derive meaningful insights from proteomics data. This includes machine learning and artificial intelligence tools that enhance data interpretation and discovery.

Business Model

Seer’s business model is centered around the integration of its proprietary technologies, services, and data analytics solutions. The company generates revenue through the sale of its Proteograph Product Suite, custom services, and licensing agreements. By offering a comprehensive ecosystem for proteomics research, Seer aims to create long-term value for its customers and stakeholders. The company also invests heavily in research and development to maintain its competitive edge and expand its product portfolio.

Strategic Direction

Seer is focused on driving innovation in proteomics and expanding its market presence. Key strategic priorities include:

  • Product Expansion: Developing new assay kits, instrumentation, and software to address emerging research needs.
  • Global Expansion: Increasing its footprint in international markets through strategic partnerships and collaborations.
  • Sustainability Goals: Implementing environmentally friendly practices in its operations and product development.
  • New Market Opportunities: Exploring applications of its technologies in areas such as diagnostics, drug discovery, and personalized medicine.

Competitive Landscape

Seer operates in a highly competitive market, with key competitors including:

  • Thermo Fisher Scientific: A global leader in life sciences tools and services.
  • Illumina: Known for its genomic sequencing technologies, which complement proteomics research.
  • Bruker Corporation: Specializes in analytical instruments for life sciences research.
  • Olink Proteomics: Focused on protein biomarker discovery and validation.

Seer differentiates itself through its proprietary technologies and focus on enabling comprehensive proteomics research.

Risk Factors

Seer faces several risks that could impact its business, including:

  • Market Dependence: Reliance on the adoption of proteomics technologies by researchers and institutions.
  • Supply Chain Disruptions: Potential delays in the production and delivery of its products.
  • Regulatory Challenges: Compliance with evolving regulations in the biotechnology and life sciences sectors.
  • Competition: Intense competition from established players and new entrants in the proteomics market.

Recent Developments

Seer has made significant strides in advancing its technologies and expanding its market presence. Recent developments include:

  • Launch of New Assay Kits: Introduction of next-generation assay kits to enhance proteomics research capabilities.
  • Strategic Partnerships: Collaborations with leading academic institutions and pharmaceutical companies to drive innovation.
  • Global Expansion: Establishment of new distribution channels in Europe and Asia.
  • COVID-19 Impact: Adaptation of its operations to address challenges posed by the pandemic, including supply chain disruptions and changes in research priorities.

Investment Considerations

Investors considering Seer should weigh the following factors:

Strengths

  • Innovative Technology: Proprietary platform with significant potential for growth.
  • Market Opportunity: Growing demand for proteomics solutions in research and healthcare.
  • Experienced Leadership: Strong management team with a track record of success.

Risks

  • Market Volatility: Fluctuations in the biotechnology sector could impact stock performance.
  • Operational Challenges: Risks associated with scaling operations and expanding globally.
  • Regulatory Risks: Potential changes in regulations that could affect the company’s business.

Conclusion

Seer, Inc. is a pioneering company in the field of proteomics, offering innovative solutions that enable researchers to explore the proteome at an unprecedented scale. With a strong focus on innovation, strategic growth, and sustainability, Seer is well-positioned to capitalize on the growing demand for proteomics technologies. While the company faces certain risks, its strengths and market opportunities make it an attractive option for investors seeking exposure to the biotechnology sector.